These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320 [TBL] [Abstract][Full Text] [Related]
28. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors. Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331 [TBL] [Abstract][Full Text] [Related]
29. Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. Lu XY; Ciraolo E; Stefenia R; Chen GQ; Zhang Y; Hirsch E Appl Microbiol Biotechnol; 2011 Mar; 89(5):1423-33. PubMed ID: 21286711 [TBL] [Abstract][Full Text] [Related]
30. Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors. Kawai K; Endo Y; Asano T; Amano S; Sawada K; Ueo N; Takahashi N; Sonoda Y; Nagai M; Kamei N; Nagata N J Med Chem; 2014 Dec; 57(23):9844-54. PubMed ID: 25383422 [TBL] [Abstract][Full Text] [Related]
31. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573 [TBL] [Abstract][Full Text] [Related]
32. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727 [TBL] [Abstract][Full Text] [Related]
33. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718 [TBL] [Abstract][Full Text] [Related]
34. Phosphoinositide 3-kinase signalling--which way to target? Wymann MP; Zvelebil M; Laffargue M Trends Pharmacol Sci; 2003 Jul; 24(7):366-76. PubMed ID: 12871670 [No Abstract] [Full Text] [Related]
35. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Sturgeon SA; Jones C; Angus JA; Wright CE Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activity of pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidin-4-one derivatives: in silico approach. Khobragade CN; Bodade RG; Dawane BS; Konda SG; Khandare NT J Enzyme Inhib Med Chem; 2010 Oct; 25(5):615-21. PubMed ID: 20001274 [TBL] [Abstract][Full Text] [Related]
37. 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2. Boyd HF; Flynn ST; Hickey DM; Ife RJ; Jones M; Leach CA; Macphee CH; Milliner KJ; Rawlings DA; Slingsby BP; Smith SA; Stansfield IG; Tew DG; Theobald CJ Bioorg Med Chem Lett; 2000 Feb; 10(4):395-8. PubMed ID: 10714508 [TBL] [Abstract][Full Text] [Related]
38. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors. Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532 [TBL] [Abstract][Full Text] [Related]
39. p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones. Natarajan SR; Wisnoski DD; Thompson JE; O'Neill EA; O'Keefe SJ Bioorg Med Chem Lett; 2006 Aug; 16(16):4400-4. PubMed ID: 16750629 [TBL] [Abstract][Full Text] [Related]